Sorrento therapeutics

[veeraveeraleaks]

 

Dr. Henry Ji,
Chairman, President and Chief Executive Officer

Henry Ji, Ph.D., co-founded and has served as a director of Sorrento since January 2006, and as its Chief Executive Officer and President since September 2012. Dr. Ji served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012 and as its Interim Chief Executive Officer from April 2011 to September 2012.

 | read more »

 

---

---

 

Jiong Shao, M.B.A.,
Executive Vice President and Chief Financial Officer

Jiong Shao is an 18-year veteran in investment banking who has held a number of senior positions with several global leading investment banks in both New York and Hong Kong.

 | read more »

 

---

Deborah H. Telman,
Senior Vice President and General Counsel

Deborah H. Telman is Senior Vice President and General Counsel. Ms. Telman will be responsible for leading Sorrento’s legal, intellectual property, compliance, human resource and quality functions and will report directly to Dr. Henry Ji, Chairman, President and CEO. Ms. Telman will also serve as Senior Vice President and General Counsel for Scilex Pharmaceuticals.

 | read more »

 

---

Alexis Nahama, D.V.M.,
Vice President of Corporate Development and President Ark Animal Health

Dr Alexis Nahama is currently Vice-President, Corporate Development, and President of Ark Animal Health (a fully owned subsidiary of Sorrento).

 | read more »

 

---

Dr. Hui Li,
Vice President of Business Development and General Manager of China Operations

Dr. Hui Li is currently Vice President of Business Development and General Manager of China Operations, a subsidiary of Sorrento Therapeutics. In this role, Dr. Li is responsible for Sorrento’s partnership set up and licensing negotiations, as well as operation of Sorrento’s Chinese subsidiaries.

 | read more »

 

---

Mark R. Brunswick, Ph.D.,
Vice President of Regulatory Affairs and Quality

Dr. Mark Brunswick has over 35 years of experience in Regulated Industry including over 9 years in the US FDA, Center for Biologics, Division of Monoclonal Antibodies.

 | read more »

 

---

Robert Knight, M.D.,
Vice President of Clinical Research

Dr. Robert Knight is a Hematologist/Oncologist with over 25 years of Pharmaceutical Industry experience. He has participated in the development of therapeutic agents for both hematologic malignancies and solid tumor cancers.

 | read more »

 

---

---

Bill Farley,
Vice President of Sales and Business Development

Bill Farley, Vice President Sales and Business Development has over 30 years’ experience in the Business Development, Sales and leading efforts in drug discovery, development and partnering.

 | read more »

[Gentle_Boy]

Same posted here

 

[veeraveeraleaks]

Chinky sanjaaalu. Already mandhu m lo pettukoni. Ippudu eee company dwara cash chesukuntaru inka

[idibezwada]

remember wht happened to lukin? risky to take any chances